



**Taro Pharmaceutical Industries Ltd.**  
**c/o Taro Pharmaceuticals U.S.A., Inc.**  
Three Skyline Drive  
Hawthorne, New York 10532  
(NYSE: TARO)

**FOR IMMEDIATE RELEASE**

**CONTACT:**

William J. Coote  
VP, CFO  
(914) 345-9001  
William.Coote@taro.com

**TARO ANNUAL REPORT ON FORM 20-F AVAILABLE**  
**For Fiscal Year Ended March 31, 2023**

**Hawthorne, NY, June 30, 2023** – Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at [www.taro.com](http://www.taro.com).

Hard copies of the report may be ordered free of charge by sending requests to:

Taro Pharmaceuticals U.S.A., Inc.  
3 Skyline Drive  
Hawthorne, NY 10532  
Attn.: William J. Coote or  
via email to [William.Coote@taro.com](mailto:William.Coote@taro.com)

Additionally, the report may be accessed on the SEC’s website at [www.sec.gov](http://www.sec.gov).

\*\*\*\*

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at [www.taro.com](http://www.taro.com).

###